The understanding of basic biologic characteristics of non-small cell lung cancer, i.e. K-ras point mutations and neuroendocrine differentiation, may aid in treatment selection and help to identify groups of patients that will benefit from adjuvant chemotherapy....
By Stephanie Stahl PHILADELPHIA (CBS) --More Americans are dying from cancer, but it's because of the aging population. The actual risk of cancer is falling. Stephanie Stahl shares a new treatment for the leading cancer killer. The new numbers from the CDC show the number of cancer deaths ...
The treatment plan for lung cancer depends on the size, location, extent of the disease, and the patient’s physical condition. In St.Stamford Modern Cancer Hospital Guangzhou, experts from Multidisciplinary Team will jointly hold a consultation and discuss appropriate treatment options for the lung...
A new inhalable dry powder treatment for lung cancer shows a significant increase in survival rates and is far less invasive than current treatment options, which frequently include radiation and surgery. This research is being presented at the 2010 International Pharmaceutical Federation (FIP) Pharmaceu...
In Norway, more than 3,300 people contract lung cancer every year. It is the second most common form of cancer among both women and men, after breast and prostate cancer, respectively. It also exhibits the highest cancer mortality rates in both sexes, ac
The emergence of new therapies in the management of lung cancer has greatly improved long-term disease control and survival rates for patients with the disease. Dr Chin Tan Min, Senior Consultant, Medical Oncology explains. Until the recent decade, conventional treatment for lung...
Non-small cell lung cancerChemotherapyPhase II drugsDavid S. EttingerLung CancerEttinger DS. New drugs in the treatment of non-small cell lung cancer. Lung Cancer 1991; 7: 113-22.Ettinger DS. New drugs in the treatment of non-small cell lung cancer. Lung Cancer 1991;7: 113–122....
Lung cancer is still the most deadly cancer. Dr. Susanna V. Ulahannan and Dr. Julie R. Brahmer of Johns Hopkins University Hospital in Baltimore, Md., provided a review of new treatment options based on combinations of standard chemotherapy agents with newer antiangiogenic drugs. Ulahannan and...
Treatment with radiation, chemotherapy, and/or surgery has evolved significantly over the last few years and treatments are now less invasive and better tolerated. That’s because treatment options for lung cancer are varied. And they may be used alone or in combination. Your doctor will discuss...
In this Seminar, we discuss existing treatment for patients with lung cancer and the promise of precision medicine, with special emphasis on new targeted therapies. Some subgroups, eg—patients with poor performance status and elderly patients—are not specifically addressed, because these groups ...